Lajos Pusztai, MD, PhD, Yale Cancer Center, discusses DNA abnormalities in breast cancer.
Pusztai says there are only three types of abnormalities that oncologists can pick up. The best examples of FDA-approved drugs for breast cancer are HER2-amplification and HER2-targeted therapies, such as trastuzumab.
Some abnormalities have also been successfully targeted in other diseases, such as EGFR mutations, which can be targeted with gefitinib in lung cancer.
A common and important question is whether or not the abnormalities in breast cancer confer the same degree of sensitivity to a targeted drug, as they do in other disease types, says Pusztai.
Lajos Pusztai, MD, PhD, professor of medicine (medical oncology), chief of Breast Medical Oncology, co-director, Cancer Genetics Research Program, Yale Cancer Center, discusses DNA abnormalities in breast cancer.
Batalini Explores Role of UGT1A1 in Patients Treated With Sacituzumab Govitecan for HR+ MBC
April 22nd 2024During a Community Case Forum live event in partnership with The Arizona Clinical Oncology Society, Felipe Batalini, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan and the impact of the UGT1A1 status on adverse event frequency.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen